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analysis from two randomised controlled triaObjective: To determine whether comorbidity presence, frequency or type is associated with Physical Activity (PA)
levels in people with Osteoarthritis (OA).
Design: Secondary data analysis of adults aged 45, with OA related pain recruited to the BEEP trial (knee pain, n
¼ 514) (ISRCTN93634563) and the MOSAICS trial (peripheral joint pain, n ¼ 525) (ISRCTN06984617).
Comorbidities considered were respiratory, cardiovascular diseases (CVD), depression, type 2 diabetes and
obesity. Self-report PA was measured using the Physical Activity Scale for the Elderly (PASE). Linear regression
models were used to estimate the mean change (β) in PA with comorbidity presence, frequency and type adjusting
for potential confounding covariates.
Results: In the BEEP trial comorbidity presence was associated with a decrease in PASE score (β ¼ -32.25 [95%
conﬁdence interval (95% CI) 48.57, 15.93]). Each additional comorbidity was associated with an incre-
mentally lower PASE score, one comorbidity (β ¼ 24.42 [-42.45, 6.38]), two comorbidities β ¼ 34.76
[-56.05, 13.48]), and three or more comorbidities β ¼ 73.71 [-106.84, 40.58]) compared to those with no
comorbidity. This pattern was similar in MOSAICS, but with a plateau in association from two comorbidities
onward. In BEEP and MOSAICS, respiratory (β ¼ 40.60 [-60.50, 20.35]; β ¼ 11.82 [-34.95, 11.31]) and CVD
(β ¼ 27.15 [-53.25, 1.05]; β ¼ 30.84 [-51.89, 9.80]) comorbidities were associated with the largest
reduction in PASE scores respectively.
Conclusion: Comorbidity presence and frequency is associated with lower PA levels and respiratory and CVD
comorbidities have the greatest impact. Future exploratory work needs to be done to understand how and why
comorbidity is associated with PA levels in people with OA.1. Introduction
Osteoarthritis (OA) frequently co-occurs with other long-term con-
ditions such as respiratory, cardiovascular diseases (CVD), depression,
type 2 diabetes and obesity [1–3]. Compared with age and gender
matched controls, those with OA are signiﬁcantly more likely to expe-
rience comorbidities [4]. It is estimated that four out of ﬁve people with
OA have at least one other long-term condition [5], with the proportion
of people with OA reporting comorbidity ranging from 68 to 85% [6].
With an ageing population, the burden of OA and comorbidity is likely to
rise in the future [1,3].
Current interventions for OA focus on alleviating pain and inﬂamma-
tion as well as improving function and quality of life (QOL) [7]. Interna-
tional clinical guidelines recommend physical activity (PA) in the form of
strengthening and aerobic exercise for everyone with OA irrespective ofKevitt).
y 2020
International (OARSI). Published
e association between comorbi
ls, Osteoarthritis and Cartilagecondition severity and comorbidity [7,8]. PA programs have been shown
to generate similar positive effects on pain and function compared to
simple analgesics and oral non-steroidal anti-inﬂammatory drugs
(NSAIDs) [9–11] in peoplewithOAbutwith lower risks of serious adverse
events [12]. PAprovides numerous health beneﬁts, including reduced risk
for many long-term conditions (e.g. type 2 diabetes and hypertension),
improved psycho-physiological health and an enhanced QOL[7–10].
However, PA interventions are underused for patients with OA [13] and
carrying out PA may become more complex in those with comorbidities.
The existenceof comorbidity creates challenges for themanagementofOA
and other long-term conditions which are largely managed according to
single condition guidelines [14]. Physiotherapists and other exercise
professionals may also ﬁnd it difﬁcult to manage individuals with several
coexisting long-term conditions due to lack of information and a lack of
conﬁdence of how to appropriately tailor PA [15].by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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S. McKevitt et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxPeople with OA have lower levels of PA than aged matched controls
and PA levels may be further compounded by comorbidities [10,16–18].
Associations between comorbidity and levels of PA have been found in
people with OA [10,16–18], however, such relationships have not been
thoroughly investigated. Further, it is unknown if speciﬁc frequencies of
comorbidity or speciﬁc types of comorbidity have more limiting effects
on PA level in people with OA and there is a dearth of evidence that
investigates OA phenotypes and comorbidity other than knee OA. This is
the ﬁrst in depth focussed investigation of comorbidity aiming to, ﬁrst,
investigate the cross-sectional association between comorbidity presence
and PA in people with OA. Second, investigate whether different fre-
quencies of comorbidity and third, different types of comorbidity are
associated with PA level. This information could inform future treatment
strategies and recommendations for OA and comorbidity adapted PA
interventions.
2. Methods
This secondary analysis study used data from two randomised
controlled trials (RCTs); The Beneﬁts of Effective Exercise for knee Pain
trial (BEEP) and The Management of OsteoArthritis In Consultations trial
(MOSAICS). These two large RCTs recruited adults with peripheral joint
pain attributed to OA, and collected self-reported PA levels, comorbidity
data, similar baseline demographics and clinical measures (further de-
tails below). Using two separate datasets allowed for comparison of
ﬁndings between different samples that include different OA phenotypes
and different methods of measuring comorbidity.
2.1. BEEP trial and participants
The BEEP trial was a multicentre, pragmatic, parallel group RCT
undertaken between 2009 and 2014 (see Foster et al; 2014 [19] for full
details). The primary aim of this trial was to determine the clinical and
cost effectiveness of two enhanced physiotherapy-led exercise in-
terventions compared with usual care. The trial included 514 adults with
pain or stiffness attributed to OA in one or both knees. The participants
were recruited from 65 general practices in England in three ways; (1)
examining medical records to identify patients consulting for knee pain
in the previous 12 months, (2) identifying patients referred to physio-
therapy for knee pain and (3) conducting a population survey of adults
(aged 45 years and over) which included a chronic pain grade to ensure
those recruited had a mean level of pain and functional difﬁculty similar
to those recruited through methods 1 and 2 [19].
2.2. MOSAICS trial and participants
The MOSAICS study was a mixed methods study with a nested cluster
RCT, undertaken between May 2011 and December 2013 [20]. The
primary aim of MOSAICS was to determine the clinical and cost effec-
tiveness of a model OA consultation (implementing the core recom-
mendations from the NICE OA guidelines in primary care) (see Dziedzic
et al, 2014 [20] for full details). 525 participants with OA, completed the
trial and agreed to primary care Medical Record Review (MRR) with data
available up to 3 years prior to index consultation for OA.
2.3. Outcomes of interest
2.3.1. Socio-demographics
Both the BEEP and MOSAICS trials datasets included participants’
socio-demographics; age, gender and partner status (yes or no).
2.4. Physical activity
PA level was measured by the self-report Physical Activity Scale for
the Elderly (PASE) in both trial datasets [21]. The scale measures leisure,
household and occupational PA with weighting speciﬁc to the frequency2and duration of each activity carried out over the previous week. The
PASE scale gives a continuous score from 0 up to 400þ, with higher
scores indicating higher PA levels. Washburn et al (1999) [21] validated
the PASE as a measure of PA suitable for use when measuring the asso-
ciation of PA, health and physical function in older adults. PASE has
acceptable retest reliability (ICC ¼ 0.77), and moderate correlation with
the IPAQ (international physical activity questionnaire) scale (r ¼ 0.61)
[22]. The PASE has been shown to have positive correlation with other
PAmeasures such as the 6-minwalk test (r¼ 0.35) and knee strength (r¼
0.41) in adults with knee pain [23].
2.5. Comorbidity
Comorbidities were the primary independent variable of interest.
Comorbidity was captured through self-report (BEEP) and MRR (MO-
SAICS). For the MRR the read code deﬁnitions for identifying comor-
bidities were derived from previous studies (for example; type 2 diabetes
[24], heart disease, asthma and Chronic Obstructive Pulmonary Disease
(COPD) [26]). In order to have consistency across the two datasets for
future comparison, the comorbidities were grouped based on type of
comorbidity.
Individual comorbidities from the two datasets were collapsed into
ﬁve overarching categories, respiratory (asthma, bronchitis, COPD), CVD
(angina, heart failure, stroke, heart attack), depression, type 2 diabetes
and obesity. Obesity was calculated from Body Mass Index (BMI)
(calculated using height and weight) and used as a dichotomous variable
(obese (BMI 30) yes/no) as well as categorical (underweight/normal
(BMI < 25), overweight (BMI 25–29.9), obese BMI  30). An a priori
decision was made not to include hypertension due to its high prevalence
and high association as a risk factor for other investigated comorbidities.
These comorbidity categories were then used to create other variables
to answer the 3 aims of this study. These were “comorbidity presence”,
which categorised participants into either having or not having any of the
ﬁve comorbidity categories (respiratory, CVD, depression, type 2 dia-
betes, obesity); “comorbidity frequency”, which counted the number of
comorbidities each individual participant had (0, 1, 2, 3þ (the frequency
of 4 and 5 comorbidities were too small to use in separate analyses,
therefore a 3þ group was formed)); “types of comorbidity” (presence of
respiratory, CVD, depression type 2 diabetes or obesity comorbidity).
2.6. Clinical variables
Physical function (as measured by Western Ontario and McMaster
Universities Arthritis Index (WOMAC) (different versions in the separate
datasets; BEEP 0–68, MOSAICS 0–32) [26]), pain (WOMAC), anxiety
(Generalised Anxiety Disorder (GAD7)) [27], quality of life (EuroQOL 5
Dimensions (EQ5D) [28] were collected. These measures are widely used
in OA clinical research and have shown to be reliable and valid and may
confound the association between comorbidity and PA [29,30].
2.7. Statistical analysis
All data analyses for this study were carried out using complete case
analysis for the BEEP and MOSAICS datasets separately using SPSS
version 24 (IBM Corp. Released 2016. IBM SPSS Statistics for Windows,
Version 24.0. Armonk, NY: IBM Corp). Descriptive statistics described
participant characteristics, independent and dependent variables.
The association between comorbidity and PA levels was estimated
using linear regression. The dependent variable for all three objectives
was PA score (PASE). The mean change in PA level (β) with 95% conﬁ-
dence interval (CI) was estimated in participants with at least one co-
morbidity compared to participants with no comorbidities (objective 1);
in participants with 1, 2 and 3þ comorbidities compared to participants
with no comorbidities (objective 2) and; in the presence of a particular
comorbidity type compared to absence of that comorbidity (objective 3).
Results were then adjusted for age, gender, partner, physical function and
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Figure 1. Proportion (%) of the BEEP and MOSAICS trial participants with
different comorbidity frequencies (0, 1, 2, 3þ).
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statistically signiﬁcant. The assumptions of linear regression and relevant
tests that were carried out to ensure these were satisﬁed are as follows; a
linear relationship (scatter plots of the independent variables against the
dependent variable), univariate normality and normal distribution of
residuals (histograms and P–P plots), little collinearity between inde-
pendent variables (Pearson's correlations and the Variance Inﬂation
Factor), no autocorrelation of residuals (Durbin-Watson statistic) and
homoscedasticity (scatter plots of the residuals against the predicted
values) [31].
Independent variables available in both datasets considered as con-
founding variables were selected based on results of past research
[32–34], theoretical and clinical importance and collinearity checks
[35]. Pairs of the independent variables were checked for collinearity
using Pearson's correlations [36]. Correlations with any r value > 0.7
dealt with by removing the variable which were considered to have less
clinical importance whilst maintaining homogeneity between datasets
[30]. The EQ5D-3L was correlated with other variables (e.g. WOMAC
function r ¼ 0.664) and considered less clinically important. WOMAC
pain and WOMAC function were highly correlated in the BEEP dataset (r
¼ 0.798), however, MOSAICS only measured WOMAC function data.
Therefore, the EQ5D-3L and WOMAC pain were removed from the
analyses.
3. Results
3.1. Baseline characteristics
Table 1 provides a summary of the descriptive statistics of partici-
pants from the BEEP and MOSAICS datasets. The BEEP and MOSAICS
trials were similar in size (n ¼ 514; 525, respectively). BEEP had slightly
more males than MOSAICS and had a slightly higher mean PASE score.
BEEP had more participants reporting presence of comorbidity. The most
common comorbidity was obesity in both datasets (see Figure 2.). The
proportion with individual comorbidity types was similar between
datasets except depression (22.2% in BEEP and 7.2% in MOSAICS)
(Figure 1, 2).Table 1
Summary of participants characteristics from the BEEP and MOSAICS trials.
BEEP MOSAICS
Total number 514 525
Age 62.85  9.79 67.34  10.47
Gender (male) 252 (49.0%) 212 (40.4%)
Partner (yes) 395 (76.8%) 373 (71.0%)
GAD7 score 3.29  4.55 3.48  4.65
WOMAC Function score# 28.08  12.26 12.19  7.28
Comorbidity presence 324 (63%) 271 (51.6%)
Respiratory 88 (17.2%) 55 (10.5%)
Cardiovascular 56 (10.9%) 65 (12.4%)
Depression 114 (22.2%) 38 (7.2%)
Type 2 diabetes 66 (12.8%) 66 (12.6%)
Obesity 191 (37.2%) 162 (30.9%)
BMI 29.63  5.67 28.26  4.96
Underweight/normal 97 (18.9%) 135 (25.7%)
Overweight 209 (40.7%) 206 (39.2%)
Obese 191 (37.2%) 162 (30.9%)
One comorbidity 189 (36.8%) 184 (35%)
Two comorbidities 98 (19.1%) 67 (12.8%)
3 þ comorbidities 37 (7.2%) 20 (3.8%)
PASE 176.90  83.51 142.67  80.28
All values are mean and standard deviation () or number and percentage (%).
BEEP¼ Beneﬁts of Effective Exercise for knee Pain, MOSAICS¼ the Management
of Osteoarthritis In Consultations, OA ¼ Osteoarthritis, PA ¼ Physical activity,
PASE ¼ PA Scale for the Elderly: 0–400þ (higher number ¼ higher PA level),
WOMAC ¼ Western Ontario and McMaster Universities Arthritis Index: #BEEP
0–68/MOSAICS 0–32 (higher ¼ worse function), GAD 7 ¼ Generalized Anxiety
Disorder 7: 0–21 (21 ¼ worst anxiety), BMI ¼ Body Mass Index, Underweight/
normal (<25), overweight (25–29.9), obese (BMI 30).
DepressionDiabetes
Figure 2. Proportion (%) of the BEEP and MOSAICS trial participants with
different comorbidity types.
33.2. Objective 1: To investigate whether comorbidity presence is associated
with PA level in adults with OA
Table 2 shows both unadjusted and adjusted associations between
PASE and comorbidity presence. Results for each objective are presented
as; beta-coefﬁcient (lower, upper 95% conﬁdence interval limits). Un-
adjusted comorbidity presence was signiﬁcantly associated with a
decrease in PASE score in BEEP β ¼ 27.93 (44.10, 11.75) and
MOSAICS β ¼ 20.86 (36.02, 5.70).
After adjusting for confounding variables (variables that may inﬂu-
ence both the dependent variable and independent variable: age,
gender, partner status, WOMAC function and GAD7), comorbidity
presence remained signiﬁcantly associated with a decrease in PASE
score in BEEP β ¼ 32.25 (48.57, 15.93) and the strength of asso-
ciation increased. In MOSAICS, however, the association between co-
morbidity presence and PASE attenuated after adjustment and was no
longer statistically signiﬁcant β ¼ 6.50 (21.11, 8.11). Increasing age
and female gender were signiﬁcantly associated with lower PASE score
in both datasets. In the BEEP dataset having a partner was associated
with an increased PASE score. In the MOSACIS dataset, worse function
(WOMAC) and worse anxiety (GAD) was associated with lower PASE
score.
Table 2
Objective 1: Unadjusted and adjusted models for objective 1: PASE score with comorbidity presence.
Independent variable BEEP MOSAICS
(N) β coefﬁcient 95% CI Lower Upper (N) β coefﬁcient 95% CI Lower Upper
Unadjusted Comorbidity presence 445 27.93* 44.10 11.75 429 20.86* 36.02 5.70
Adjusted Comorbidity presence 390 32.25* 48.57 15.93 405 6.50 21.11 8.11
Age 2.49* 3.36 1.63 2.48* 3.20 1.76
Gender (female) 18.59* 34.21 2.97 25.32* 39.57 11.06
Partner (yes) 30.22* 7.73 52.70 14.89 1.54 31.31
WOMAC function# -0.24 -0.92 0.43 1.58* 2.69 0.46
GAD7 1.57 3.34 0.21 2.08* 3.75 0.41
Unadjusted and adjusted models for objective 1 in BEEP and MOSAICS datasets.
*denotes statistically signiﬁcant at p < 0.05.
Footnotes: complete case data, multiple linear regression adjusted for age, gender, partner, WOMAC function and GAD7. β coefﬁcient represents mean change in PASE
score. Higher PASE scores indicate higher levels of PA. Age (increase in one year); Gender (reference: male); Partner (reference: no partner); Higher WOMAC function
indicates worse function (one increase unit in WOMAC function score, # BEEP 0–68/MOSAICS 0–32); Higher GAD7 indicates worse anxiety (one increase unit in GAD7
score).
Abbreviations: β: unstandardized beta coefﬁcient; CI: Conﬁdence Interval; WOMAC: Western Ontario and McMaster Osteoarthritis Index; GAD7: Generalised Anxiety
Disorder Questionnaire.
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associated with PA level in adults with OA
In BEEP, the unadjusted associations found each additional comor-
bidity was signiﬁcantly associated with a lower PASE score; one co-
morbidity β ¼ 19.85 (38.11, 1.59), two comorbidities β ¼ 32.72
(53.91,11.52), and three or more comorbidities β¼52.68 (83.42,
21.94) compared to those with no comorbidity. After adjusting for
confounding variables, comorbidity frequency remained signiﬁcant and
grew in association with lower PASE scores across all frequencies of
comorbidity; one comorbidity β ¼ 24.42 (42.45, 6.38); two
comorbidities β ¼ 34.76 (56.05, 13.48) and three or more comor-
bidities β ¼ 73.71 (106.84, 40.58).
The unadjusted and adjusted models for MOSAICS found having
one comorbidity was not signiﬁcantly associated with PASE score; 0;
β ¼ 8.51 (25.11, 8.08) compared to no comorbidity. However,
having two comorbidities β ¼ 45.06 (68.45, 21.66) and three
or more comorbidities β ¼ 52.25 (91.39, 13.11) were signiﬁ-
cantly associated with an incremental decrease in PASE scores
compared to no comorbidity. In adjusted analyses associations
attenuated. Having one comorbidity remained non-signiﬁcant
β ¼ 1.39 (14.30, 17.08). Having three or more comorbidities
was no longer signiﬁcantly associated with PASE score β ¼ 24.70
(62.15, 12.76). However, presence of two comorbidities remained
signiﬁcantly associated with a decrease in PASE score β ¼ 26.84
(49.30, 4.38) (Table 3).Table 3
Objective 2: Unadjusted and adjusted models for BEEP and MOSAICS PASE score an
Independent variable BEEP
(N) β coefﬁcient 95% CI Low
Unadjusted 1 comorbidity 445 19.85* 38.11
2 comorbidities 445 32.72* 53.91
3þ comorbidities 445 52.68* 83.42
Adjusted 1 comorbidity 390 24.42* 42.45
2 comorbidities 390 34.76* 56.05
3þ comorbidities 390 73.71* 106.84
PASE score for each comorbidity category variable (reference 0 comorbidity).
*denotes statistically signiﬁcant at p < 0.05.
Footnotes: complete case data, multiple linear regression adjusted models adjusted
PASE score. Higher PASE scores indicate higher levels of PA.
Abbreviations: β ¼ unstandardized beta coefﬁcient; CI¼ Conﬁdence Interval; WOM
Anxiety Disorder Questionnaire.
43.4. Objective 3: To investigate whether different types of comorbidity are
associated with PA level in adults with OA
In BEEP, respiratory, type 2 diabetes and obesity comorbidities were
all signiﬁcantly associated with a decrease in PASE score (Table 4).
Respiratory had the strongest association with lower PASE scores
β ¼ 40.11 (60.07, 20.14), followed by type 2 diabetes β ¼ 26.68
(48.82, 4.55) and obesity β ¼ 25.78 (41.06, 9.50). CVD
(β ¼ 25.75 (48.04, 0.54)) and depression (β ¼ 3.12 (15.53, 21.76))
were not signiﬁcantly associated with PASE score.
Respiratory β ¼ 40.6 (60.5, 20.35), type 2 diabetes β ¼ 30.19
(54.25, 6.12) and obesity β ¼ 27.72 (44.08, 11.36) remained
associated with lower PASE score in the adjusted models (Table 4) and
CVD (β ¼ 27.15 (53.25, 1.05) was now signiﬁcant. Depression
remained non-signiﬁcant; β ¼ 4.93 (23.62, 13.76).
In MOSAICS, the unadjusted models (Table 4), showed CVD
β ¼ 43.00 (65.08, 20.91) and type 2 diabetes β ¼ 34.42 (56.64,
12.20) were signiﬁcantly associated with a decrease in PASE score.
Respiratory and depression were non-signiﬁcantly associated with PASE
scores, but estimates suggest a negative association; β¼22.43 (46.98,
2.12), β ¼ 23.24 (53.06, 6.58); respectively. Obesity had the smallest
magnitude of association and was non-signiﬁcant; β ¼ 7.62 (24.12,
8.88).
After adjusting for confounding variables, only CVD conditions
remained signiﬁcant and had the strongest magnitude of association with
PASE scores; β ¼ 30.84 (51.89, 9.80). Respiratory β ¼ 11.82d comorbidity frequency.
MOSAICS
er Upper (N) β coefﬁcient 95% CI Lower Upper
1.59 429 8.51 25.11 8.08
11.52 429 45.06* 68.45 21.66
21.94 429 52.25* 91.39 13.11
6.38 405 1.39 14.30 17.08
13.48 405 26.84* 49.30 4.38
40.58 405 24.70 62.15 12.76
for age, gender, partner, WOMAC and GAD7. β coefﬁcient represents change in
AC: Western Ontario and McMaster Osteoarthritis Index; GAD7 ¼ Generalised
Table 4
Objective 3: Unadjusted and adjusted models for BEEP and MOSAICS PASE score and comorbidity type.
Independent variable BEEP MOSAICS
(N) β coefﬁcient 95% CI Lower Upper (N) β coefﬁcient 95% CI Lower Upper
Unadjusted Respiratory 463 40.11* 60.07 20.14 432 22.43 46.98 2.12
Cardiovascular 463 23.75 48.04 0.54 432 43.00* 65.08 20.91
Depression 462 3.12 15.53 21.76 432 23.24 53.06 6.58
Type 2 diabetes 463 26.68* 48.82 4.55 432 34.42* 56.64 12.20
Obesity 448 25.28* 41.06 9.50 430 7.62 24.12 8.88
BMI Categorical (reference <25)
Overweight (25–29.9) 448 21.84* 0.25 43.44 413 3.11 16.21 22.42
Obese (30þ) 448 9.83 31.75 12.09 413 5.62 26.08 14.84
Adjusted Respiratory 403 40.60* 60.50 20.35 408 11.82 34.95 11.31
Cardiovascular 403 27.15* 53.25 1.05 408 30.84* 51.89 9.80
Depression 402 4.93 23.62 13.76 408 10.27 38.45 17.92
Type 2 diabetes 403 30.19* 54.25 6.12 408 17.03 38.11 4.05
Obesity 393 27.72* 44.08 11.36 406 1.71 13.94 17.35
BMI Categorical (reference <25)
Overweight (25–29.9) 393 12.17 9.68 34.02 392 3.37 21.57 14.83
Obese (30þ) 393 18.65 41.73 4.42 392 -0.46 20.20 19.28
PASE score for each comorbidity and BMI category variable (reference: underweight/normal).
*denotes statistically signiﬁcant at p < 0.05.
Footnotes: complete case data, multiple linear regression adjusted models adjusted for age, gender, partner, WOMAC and GAD7. β coefﬁcient represents change in PASE
score. Higher PASE scores indicate higher levels of PA.
Abbreviations: β ¼ unstandardized beta coefﬁcient; CI¼ Conﬁdence Interval; WOMAC: Western Ontario and McMaster Osteoarthritis Index; GAD7 ¼ Generalised
Anxiety Disorder Questionnaire.
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diabetes β ¼ 17.03 (38.11, 4.05) were no longer signiﬁcantly asso-
ciated with PASE scores, with a weaker but still negative association
whilst obesity β ¼ 1.71 (13.94, 17.35) was not signiﬁcantly associated.
The relationship between BMI as a categorical variable and PA is also
included at the bottom of both the BEEP andMOSAICSmodels in Table 4.
4. Discussion
This is the ﬁrst study to investigate and describe in detail the asso-
ciation between comorbidity and PA in people with OA. Comorbidity
presence was associated with lower PA level. Our ﬁndings suggest a
potential dose-response relationship with activity levels decreasing as the
number of comorbidities increase in people with OA. This relationship
was more pronounced in the BEEP trial than in the MOSAICS trial.
Distinct comorbidity types had different magnitudes of association with
lower PA levels across both datasets.
People with OA commonly also have other comorbidities [1,2]. In the
current study samples, of the comorbidities under investigation, obesity
had the highest prevalence; 37.2% and 30.9% in BEEP and MOSAICS
trials, respectively. Reeuwijk et al (2010) [37] found obesity prevalence
to be lower at 23.9% in a cohort of people with hip and knee OA in the
Netherlands. Other comorbidity rates in their OA sample were similar to
our ﬁndings, respiratory: 15.6%, CVD (cardiac event, coronary and
stroke): 10.1% and type 2 diabetes: 9.7% [37].
Within the BEEP and MOSAICS trials, the reported levels of condi-
tions such as obesity, type 2 diabetes and CVD disease, that have clear
diagnostic features, appear to be similar for both self-report and MRR.
However, there was some inter-dataset variation in terms of sample
proportion with other comorbidity types. Depression appears to be under
reported in MOSAICS compared to BEEP. This may be due to general
practitioners using a variety of codes for recording symptoms associated
with depression, or not all cases of depression being discussed or recor-
ded [38]. Research has shown that the stigma of reporting depression
may make people reluctant to seek professional help; although 20–40%
of community dwelling older people show signs of depression, fewer than
10% consult a general practitioner [39].
Previous research on community dwelling older adults also showed
PASE scores to be higher for healthy participants: 155 (males ¼ 172;
females ¼ 139) compared to those with health conditions, ranging from5118 to 139 [40]. Our ﬁndings of lower levels of PA in people with OA and
comorbidity presence are similar to those reported in a systematic review
of correlates of PA in people with knee and hip OA by Stubbs et al (2015)
[16]. Stubbs and colleagues found PA level was reduced with higher BMI
and comorbidity presence [16]. Similar to our multivariable models,
increased age, worse OA symptoms, female gender have been found to be
associated with lower levels of PA [16].
In our cross-sectional analyses, comorbidity presence was signiﬁ-
cantly associated with PA level in the BEEP adjusted model. This supports
previous studies demonstrating that OA combined with another long-
term condition, increased the likelihood of lower PA levels [16–18]. In
a study by Cook et al (2018) [41], the presence of comorbidity was
associated with reduced PA in the general population and to a greater
extent in those with inﬂammatory rheumatic or musculoskeletal disease
(IRMD). Speciﬁcally, myocardial and vascular comorbidities and
depression were associated with reduced odds of moderate or high level
of PA in those with IRMD [41]. These results support the ﬁndings of our
study as both CVD and depression reduced PA levels in the models.
Addressing the second aim, in the current study, as comorbidity
frequency increased, PASE score declined. In BEEP, the addition of
one, two and three or more comorbidities was incrementally associated
with a greater magnitude of difference in PASE score. A similar pattern
was observed in the MOSAICS dataset, but with a plateau in the affect
from 2 comorbidities upwards. Similarly, increased comorbidity
burden has previously been shown to be associated with reduced odds
of reporting moderate to high levels of PA in participants with IRMD
[41]. Low levels of PA and more sedentary time are key risk factors for
multiple long-term conditions such as type 2 diabetes, obesity and CVD
[42].
Higher frequency of comorbidities may lead to more barriers to car-
rying out regular PA. For example, living with multiple long-term con-
ditions can add complexity to carrying out PA by potentially reducing
physical performance and inﬂuencing psychological factors [43,44],
such as self-efﬁcacy for exercise [45]. Barriers to the uptake and main-
tenance of PA in those with OA have been investigated previously and
include a lack of knowledge or belief in the beneﬁts of exercise and low
self-efﬁcacy [45,46]. Low self-efﬁcacy for exercise is also associated with
lower levels of PA in people with other conditions such as type 2 diabetes
[47] and it is possible that living with multiple long term conditions may
have a cumulative negative effect on self-efﬁcacy for exercise which in
S. McKevitt et al. Osteoarthritis and Cartilage Open xxx (xxxx) xxxturn may contribute to lower levels of PA.
In the models investigating speciﬁc types of comorbidity, a greater
number of comorbidity types were found to be associated with PASE
score in BEEP than in MOSAICS. This could be explained by the different
methods for measuring comorbidity or the different types of OA included
in the MOSAICS sample possibly being less associated with PA (e.g. hand
OA). CVD comorbidity was consistently signiﬁcantly associated with a
reduction in PASE scores in both datasets. CVD comorbidity existed in
just over 10% of both trial datasets. In primary care, patients with OA and
CVD have greater baseline OA pain, symptom burden and functional
limitations, speciﬁcally walking disability [48] whichmay in part explain
their lower levels of PA.
Physical health comorbidities such as respiratory conditions and type
2 diabetes had a negative association with PASE scores in the current
study. People with type 2 diabetes or respiratory conditions may be
excluded from PA treatment or be recommended PA that is suboptimal.
This could be due to concerns from health care practitioners regarding
comorbidity speciﬁc physiological factors (e.g. hypoglycaemia in type 2
diabetes), symptoms (e.g. breathlessness in respiratory conditions) and
adverse events during PA [49].
4.1. Strengths and limitations
A strength of this study was the use of two large RCT datasets,
different OA joint phenotypes and two methods for the measurement of
comorbidity (self-report and MRR) which makes the results more gen-
eralisable to different OA populations. The range of comorbidities
investigated within this study are those that most commonly exist
alongside OA and are likely to inﬂuence PA behaviour [7]. The use of
multiple linear regression meant that we could adjust for known con-
founders in the models.
A limitation of our secondary data analysis is that it was not possible
to investigate all comorbidities that may inﬂuence PA or adjust for
confounding variables not captured on the original datasets. We were
unable to investigate the role of comorbidity severity which is of interest
as it may inﬂuence the relationship between comorbidity presence or
frequency and PA level. Also, medication use for speciﬁc comorbidities
could act as either confounders or effect modiﬁers. The cross-sectional
nature of our study prevents us inferring causation in our ﬁndings and
it is possible that a reciprocal relationship exists where comorbidities
may be both risk factors for, or a result of, reduced PA in the samples.
The use of a self-reported PA measure in both trials could be criticised
as objectively measured PA is seen as the preferred method of mea-
surement. Although there is some evidence for the validity of PASE for
use in OA populations, in people with hip OA the PASE has a relatively
large standard error of measurement (SEM) of 31, also it may still be
prone to self-report bias including recall bias, misclassiﬁcation and the
over/underestimation of PA level [50]. There is no accepted clinically
important change in PASE in the literature which limits our ability to
interpret whether the reductions of PA associated with different comor-
bidities are of clinical importance. It is acknowledged that there was
some missing data which may inﬂuence the ﬁndings by reducing the
statistical power or producing biased estimates. Levels of missing data
were generally low in both datasets with levels of outcome PASE missing
data 10% in BEEP and 18% in MOSAICS. Finally, although the BEEP and
MOSAICS trial samples were similar to people with OA in primary care
and community settings in the UK, generalisability is limited to the
eligibility of both study protocols. For example, these datasets excluded
people with joint replacements, those unable to access physiotherapy or
General Practice and those residing in nursing homes who may have
more severe comorbidities or be of an older age.
4.2. Future research and clinical recommendations
Although our ﬁndings showed comorbidity to be associated with self-
report PA in people with OA, it did not investigate how and why this6might be the case. Hence, qualitative explanatory research exploring
attitudes and beliefs and experiences of the impact that comorbidities
have on PA in people with OA is indicated. Further work could also
identify ways to overcome barriers to PA in the presence of OA and co-
morbidity. Our ﬁndings suggest that interventions tailored to increasing
PA in people with OA and comorbidity are required since this group is at
high risk of low PA levels due to the existence of their comorbidity.
5. Conclusion
In conclusion, in patients with OA, comorbidity is associated with
lower PA levels and this association grows in magnitude with increasing
comorbidity frequency. People with OA and certain types of comorbidity
such as respiratory and CVD disease may be important to subgroup in
terms of PA interventions. Future exploratory work needs to be done to
understand how and why comorbidity is associated with PA levels in
people with OA.
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